is there any hope of getting vendors to offer SS-31 at standard dosages?

[clayd]

SS-31 appears to be a very promising drug candidate with a host of potential benefits, including improved vision, brain health, cleaning up of free radicals, movement/mobility, and exercise performance.

but the clinical trials i've read use dosages of 40-60mg/day for like 24 weeks. That's between 6700mg and 10000mg for a full course. Currently vendors sell kits with 100-250mg for the $100-200 range approximately, meaning you'd need 25-30 kits for a full course. That's over $5000.

the peptide people seem to like 2-4mg doses daily, but it would be good if the vendors wanted to compete on a full regimen for a reasonable price.
is there any chance of engaging with vendors to make this happen? or are they just selling stuff with a markup vs. their production cost?

 

[RocketGotRobbed]

Those are therapeutic disease-targeting doses aimed at sick populations (mitochondrial myopathy, heart failure, Barth syndrome) where aggressive intervention was justified. When longevity clinics began recommending a much smaller dose for us labrats, it was because:
1. Risk vs. reward — If not in a disease state like end-stage cardiomyopathy, then you’re layering SS-31 into a broad longevity / optimization protocol with others (think NAD+, MOTS-c, Retatrutide, KLOW, etc.) A lower “signal dose” is more about nudging mitochondrial resilience rather than going all-in on a pharmaceutical-strength rescue.
2. Safety + supply — Most physicians using SS-31 off-label in wellness/athletic settings use 5–10 mg SC daily or every other day, an order of magnitude lower, and still report subjective improvements in recovery, endurance, or fatigue. Once these anecdotal findings spread through the community, others joined in and found similar success.

There are many reports from clinics who pushed clientele near clinical doses and found no additional benefits. But I get it.

 

[rkl123]

Those are therapeutic disease-targeting doses aimed at sick populations (mitochondrial myopathy, heart failure, Barth syndrome) where aggressive intervention was justified. When longevity clinics began recommending a much smaller dose for us labrats, it was because:
1. Risk vs. reward — If not in a disease state like end-stage cardiomyopathy, then you’re layering SS-31 into a broad longevity / optimization protocol with others (think NAD+, MOTS-c, Retatrutide, KLOW, etc.) A lower “signal dose” is more about nudging mitochondrial resilience rather than going all-in on a pharmaceutical-strength rescue.
2. Safety + supply — Most physicians using SS-31 off-label in wellness/athletic settings use 5–10 mg SC daily or every other day, an order of magnitude lower, and still report subjective improvements in recovery, endurance, or fatigue. Once these anecdotal findings spread through the community, others joined in and found similar success.

There are many reports from clinics who pushed clientele near clinical doses and found no additional benefits. But I get it.

There's also the fact that even amongst the folks it is designed for/tested on it has hardly done anything. It's trials have been quite mediocre.